A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
a study on Diabetes Diabetes Type 2 Chronic Kidney Disease Kidney Disease
Summary
- Eligibility
- for people ages 30-80 (full criteria)
- Location
- at UC Davis
- Dates
- study startedcompletion around
Description
Summary
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
Official Title
A Phase 3 Randomized Controlled Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 2 Diabetes and Chronic Kidney Disease (REGEN-006)
Details
Randomized multi-center, blinded intervention, two cohort, study whereby eligible participants will be randomized 1:1, prior to kidney biopsy, to 1 of 2 cohorts. Cohort 1 participants will undergo sham procedures and be followed to the global trial end date. Cohort 2 participants will receive 2 REACT injections 3 months apart (+30 days) and be followed to the global trial end date. This event driven study is estimated to have a total maximum duration of 5 years.
Keywords
Type 2 Diabetes Mellitus, Chronic Kidney Diseases, REACT®, Rilparencel, Kidney Diseases, Chronic Renal Insufficiency, Diabetes Mellitus, Renal Autologous Cell Therapy (REACT)
Eligibility
You can join if…
Open to people ages 30-80
- The participant is male or female, 30 to 80 years of age on the date of informed consent.
- The participant has a clinical diagnosis of T2DM in their health record.
- The participant has a clinical diagnosis of diabetic nephropathy as the underlying cause of renal disease (diagnosis does not have to be confirmed via renal biopsy) in their health record.
- The participant has a serum glycosylated hemoglobin (HbA1c) less than 9.5% at the Screening Visit.
The participant has a documented clinical diagnosis of either:
eGFR greater than or equal to 20 and less than 30 mL/min/1.73m², not requiring renal dialysis. UACR level cannot exceed 5000 mg/g (565 mg/mmol) OR: eGFR of 30 to less than or equal to 35 mL/min/1.73m² AND UACR of 300 to less than or equal to 5000mg/g (33.9 mg/mmol to less than or equal to 565 mg/mmol).
- Systolic blood pressure of ≤ 140 mm Hg and diastolic blood pressure of ≤ 90 mm Hg at Screening (based on the average of 3 measurements obtained while seated) and maintained during the screening period until randomization.
- On a clinically relevant and stable dose of an angiotensin converting-enzyme inhibitor (ACEI) OR an angiotensin receptor blocker (ARB), unless not tolerated or contraindicated.
You CAN'T join if...
- The participant has a history of type 1 diabetes mellitus.
- The participant has a history of renal transplantation or other organ transplantation (corneal transplants are not an exclusion), solitary kidney, recurrent complicated urinary tract infections or complicated kidney stones. Urinary tract infections identified prior to renal biopsy or injection should be resolved prior to procedures.
- The participant has any other known underlying cause of kidney disease, including but not limited to: Autosomal dominant and recessive polycystic kidney disease, primary focal segmental glomerulosclerosis, vasculitis related CKD, IgA nephropathy and other immune modulated nephropathies, drug-induced CKD or other types of CKD or anatomic variants as determined by the Investigator or Sponsor that would interfere with biopsy and REACT injection procedure or confound study assessments.
- History of acute kidney injury within 3 months prior to the Screening Visit.
- Myocardial infarction, unstable angina, revascularization procedure (e.g. stent or bypass graft surgery), or cerebrovascular accident within 12 weeks before randomization, or a revascularization procedure is planned during the trial.
Locations
- UC Davis Medical Group GI Unit
accepting new patients
Sacramento California 95817 United States - Allameh Medical Corporation
in progress, not accepting new patients
Mission Viejo California 92691 United States - Valley Renal Medical Group
accepting new patients
Northridge California 91324 United States - Valley Clinical Trials
accepting new patients
Northridge California 91325 United States - IMD Clinical Trials
in progress, not accepting new patients
Huntington Park California 90255 United States - Medicine and Nephrology Associates
accepting new patients
Los Alamitos California 90720 United States - Academic Medical Research Institute
accepting new patients
Los Angeles California 90022 United States - Integrity Medical Discovery
in progress, not accepting new patients
Pico Rivera California 90660 United States - Advanced Medical Research, LLC
accepting new patients
Lakewood California 90712 United States
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Prokidney
- ID
- NCT05099770
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 685 study participants
- Last Updated